Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Peripheral artery disease (PAD) can lead to gangrene or amputation yet is often overlooked - experts have warned that just ...

A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...

Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...

Coronary artery disease (CAD) continues to be a leading cause of morbidity and mortality globally. The recommendations that ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

Heart disease remains the leading cause of death for both men and women across America, but emerging research reveals a ...

Researchers have created an AI tool to accelerate the development of new disease treatments and demonstrated its potential by identifying an existing drug with the potential to prevent deadly heart ...

When pregnant patients and their families receive a prenatal diagnosis of a congenital heart defect (CHD), it sparks ...